Berkshire Hathaway's shares have edged past its industry, backed by insurance growth, rising float, strong cash and expanding ...

AbbVie ABBV and AstraZeneca AZN are both global healthcare companies with diversified drug portfolios. Both companies have ...

AstraZeneca AZN stock has declined 6.4% in the past three months. Although AstraZeneca faces its share of challenges, a significant portion of this price decline is attributed to broader market ...

That morning, U.K. newspaper The Times published an article stating that AstraZeneca CEO Pascal Soriot aims to move the company's stock market listing onto our shores (ADSes are certificates ...

AstraZeneca’s ($AZN) breast cancer drug Enhertu has been granted Breakthrough Therapy Designation by the U.S. Food and Drug ...

It might be gearing up to pay billions of dollars to participate in a drug program currently in development. Its would-be partner is an American biotech that has earned a lot of attention lately. A ...

AstraZeneca aims for $80bn revenue by 2030, highlighting oncology advances and growth potential. See AZN stock's valuation insights and GARP investment case.

​AstraZeneca PLC (NASDAQ: AZN) is one of the Best Non-US Stocks to Buy According to Hedge Funds. On December 16, AstraZeneca ...

AstraZeneca AZN stock has risen 15% so far this year compared with an increase of 0.2% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below.

AstraZeneca's shares jumped after Pfizer's announcement of a major deal with the Trump administration. Pfizer's good news could benefit AstraZeneca, too. Pfizer CEO Albert Bourla appeared with ...